Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:SCNX NASDAQ:TRAW NASDAQ:XRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.68-0.7%$0.80$0.57▼$2.48$15.33M1.05613,341 shs167,089 shsSCNXScienture$0.41+5.5%$0.40$0.24▼$2.60$16.74M3.322.53 million shs328,898 shsTRAWTraws Pharma$1.65+4.2%$1.65$0.97▼$3.27$16.71M1.47207,150 shs25,866 shsXRTXXORTX Therapeutics$2.78+0.2%$2.24$1.73▼$7.05$3.86M0.8913,551 shs5,715 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-1.86%+5.68%-19.57%-10.94%-15.19%SCNXScienture-2.64%+2.01%+31.83%-15.22%-58.44%TRAWTraws Pharma+6.04%+30.58%-3.66%-18.56%+5.33%XRTXXORTX Therapeutics-0.36%0.00%+28.99%+10.27%-45.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.68-0.7%$0.80$0.57▼$2.48$15.33M1.05613,341 shs167,089 shsSCNXScienture$0.41+5.5%$0.40$0.24▼$2.60$16.74M3.322.53 million shs328,898 shsTRAWTraws Pharma$1.65+4.2%$1.65$0.97▼$3.27$16.71M1.47207,150 shs25,866 shsXRTXXORTX Therapeutics$2.78+0.2%$2.24$1.73▼$7.05$3.86M0.8913,551 shs5,715 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals-1.86%+5.68%-19.57%-10.94%-15.19%SCNXScienture-2.64%+2.01%+31.83%-15.22%-58.44%TRAWTraws Pharma+6.04%+30.58%-3.66%-18.56%+5.33%XRTXXORTX Therapeutics-0.36%0.00%+28.99%+10.27%-45.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.00Hold$6.00779.77% UpsideSCNXScienture 2.00Hold$1.50264.08% UpsideTRAWTraws Pharma 2.50Moderate Buy$8.00386.03% UpsideXRTXXORTX Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest XRTX, SCNX, CTXR, and TRAW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026TRAWTraws Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D+)3/27/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026SCNXScienture Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026XRTXXORTX Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/11/2026CTXRCitius Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.002/24/2026SCNXScienture Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$1.50(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius PharmaceuticalsN/AN/AN/AN/A$4.29 per shareN/ASCNXScienture$430K38.93N/AN/A$1.73 per share0.24TRAWTraws Pharma$2.79M5.99$0.95 per share1.74($0.08) per share-20.58XRTXXORTX TherapeuticsN/AN/AN/AN/A$1.50 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$37.43M-$2.45N/AN/AN/AN/A-49.34%-28.64%5/13/2026 (Estimated)SCNXScienture-$41.51M-$2.76N/AN/AN/AN/A-53.25%-41.55%5/11/2026 (Estimated)TRAWTraws Pharma$9.17M$0.931.77N/AN/AN/A112.18%35.31%5/18/2026 (Estimated)XRTXXORTX Therapeutics-$2.66M-$3.00N/AN/AN/AN/A-120.32%-90.53%5/14/2026 (Estimated)Latest XRTX, SCNX, CTXR, and TRAW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q4 2025TRAWTraws Pharma-$0.51N/AN/AN/A$0.06 millionN/A5/13/2026Q2 2026CTXRCitius Pharmaceuticals$0.3885N/AN/AN/A$18.79 millionN/A5/11/2026N/ASCNXScienture-$0.23N/AN/AN/A$0.40 millionN/A4/15/2026Q4 2025TRAWTraws Pharma-$1.2238-$0.71+$0.5138-$0.71$0.06 millionN/A3/30/2026Q4 2025SCNXScienture-$0.28-$1.76-$1.48-$1.76$0.49 million($0.17) million2/26/2026Q4 2025XRTXXORTX TherapeuticsN/A-$0.45N/A-$0.09N/AN/A2/13/2026Q1 2026CTXRCitius PharmaceuticalsN/A-$0.38N/A-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/ASCNXScientureN/AN/AN/AN/AN/ATRAWTraws PharmaN/AN/AN/AN/AN/AXRTXXORTX TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.990.40SCNXScientureN/A2.892.82TRAWTraws PharmaN/A0.720.72XRTXXORTX TherapeuticsN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%SCNXScienture5.68%TRAWTraws Pharma7.95%XRTXXORTX Therapeutics0.23%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals4.99%SCNXScienture21.39%TRAWTraws Pharma14.00%XRTXXORTX Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2022.38 million21.26 millionOptionableSCNXScientureN/A40.63 million31.94 millionN/ATRAWTraws Pharma1710.16 million8.74 millionNo DataXRTXXORTX TherapeuticsN/A1.39 million1.30 millionNot OptionableXRTX, SCNX, CTXR, and TRAW HeadlinesRecent News About These CompaniesXORTX Therapeutics (NASDAQ:XRTX) Stock Passes Above 200-Day Moving Average - Should You Sell?May 5 at 2:53 AM | americanbankingnews.comFinancial Analysis: XORTX Therapeutics (NASDAQ:XRTX) versus Sandoz Group (OTCMKTS:SDZNY)May 1, 2026 | americanbankingnews.comXORTX Regains Nasdaq Listing Compliance After Reverse Stock SplitApril 23, 2026 | theglobeandmail.comXORTX Therapeutics jumps as it confirms Nasdaq bid-price compliance after reverse splitApril 21, 2026 | quiverquant.comQXORTX Meets Nasdaq Continued Listing RequirementsApril 21, 2026 | financialpost.comFXORTX Closes US$3 Million Acquisition of Vectus Kidney Anti‑Fibrotic ProgramApril 16, 2026 | tipranks.comXORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic AssetApril 13, 2026 | financialpost.comFXORTX Therapeutics Secures Exchange Approvals for 1-for-5 Share Consolidation Effective April 6April 1, 2026 | tipranks.comXORTX Confirms Effective Date of Share ConsolidationApril 1, 2026 | markets.businessinsider.comXORTX Confirms Effective Date of Share ConsolidationApril 1, 2026 | financialpost.comFXORTX Confirms Effective Date of Share ConsolidationApril 1, 2026 | globenewswire.comXORTX Therapeutics Inc.: XORTX Announces Results of Annual and Special Meeting of ShareholdersMarch 27, 2026 | finanznachrichten.deXORTX Therapeutics Inc.: XORTX Announces Change of Effective Date of Share ConsolidationMarch 27, 2026 | finanznachrichten.deXORTX Shareholders Approve Governance Measures and Share Consolidation at Annual MeetingMarch 26, 2026 | tipranks.comXORTX Announces Results of Annual and Special Meeting of ShareholdersMarch 26, 2026 | financialpost.comFXORTX Announces Results of Annual and Special Meeting of ShareholdersMarch 26, 2026 | globenewswire.comXORTX Therapeutics Inc.: XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General MeetingMarch 26, 2026 | finanznachrichten.deXORTX Announces Change of Effective Date of Share ConsolidationMarch 26, 2026 | financialpost.comFXORTX Announces Change of Effective Date of Share ConsolidationMarch 26, 2026 | globenewswire.comXORTX Announces Share ConsolidationMarch 25, 2026 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXRTX, SCNX, CTXR, and TRAW Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$0.68 -0.01 (-0.73%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Scienture NASDAQ:SCNX$0.41 +0.02 (+5.48%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.Traws Pharma NASDAQ:TRAW$1.65 +0.07 (+4.18%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.XORTX Therapeutics NASDAQ:XRTX$2.78 +0.01 (+0.18%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
